Promega Launches Novel ADCC Reporter Bioassay for Biologics
Frozen, Thaw-and-Use Cells Reduce Variability Compared to PBMCs and NK Cells
MADISON, WISCONSIN (October 10, 2012)
Promega Corporation announces the introduction of a novel bioluminescent assay for the quantification of Fc effector function of antibody-based molecules in the development and manufacture of biologic drugs. The assay is ADCC mechanism of action (MOA)-based and features frozen, thaw-and-use effector cells, and optimized reagents and protocol to perform a reporter-based ADCC bioassay in a single day. The ADCC Reporter Bioassay correlates with classic cytotoxic ADCC assays and is a suitable replacement for these cumbersome and highly variable assays.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is the main MOA of antibodies through which virus-infected or other diseased cells are targeted for destruction by components of the cell-mediated immune system, such as natural killer cells.
The ADCC Reporter Bioassay uses an alternative readout at an earlier point in ADCC MOA pathway: the activation of gene transcription through the NFAT (nuclear factor of activated T-cells) pathway in the effector cell. In addition, the bioassay uses engineered Jurkat cells stably expressing the FcγRIIIa receptor, V158 (high affinity) variant, and an NFAT response element driving expression of firefly luciferase.
Following extensive in-house studies and a successful alpha trial program, the ADCC Reporter Bioassay is now being adopted by global biologics companies as well as being offered as a service by Charles River Laboratories. The novel bioassay is linear, accurate, precise and stability indicating. Moreover, the bioassay shows good linear correlation between levels of glycosylation or fucosylation and ADCC activity. All of these features indicate the assay is suitable for use across biologic drug development programs.
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.
These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.
For more information about a new release article or about Promega in general, contact Penny Patterson at 1-608-274-4330 or complete this form.